Genetic Risk Prediction for Primary and Secondary Prevention of Atherosclerotic Cardiovascular Disease: an Update
Purpose of Review
This review aims to summarize the research on genetic risk scores and their ability to improve risk prediction in both a primary and a secondary prevention population.
Several groups have examined the role of genetic scores in different patient populations. Recent studies have capitalized on the growing number of identified genetic variants to construct polygenic risk scores that include hundreds and sometimes thousands of SNPs. Also, recent studies have demonstrated that individuals with high genetic risk scores can attenuate their risk with lifestyle modifications and with statins, for which the benefit of treatment may be greater in those at highest genetic risk.
Genetic risk scores when added to existing clinical models appear to improve risk prediction, particularly in the setting of incident cardiovascular disease and may provide actionable information to optimize prevention early in life. Future research will need to establish how to best use this genetic risk information either as a means to further individualize treatment decisions or to better identify high-risk populations.
KeywordsGenetic risk score Single nucleotide polymorphism Risk prediction Prevention
Compliance with Ethical Standards
Conflict of Interest
Christopher Labos declares that he has no conflict of interest.
Dr. Thanassoulis reports grants and personal fees from Ionis; and personal fees from Amgen, Sanofi, and Servier.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 4.Dawber TR, Kannel WB, Revotskie N, Stokes J, Kagan A, Gordon T. Some factors associated with the development of coronary heart disease: six years' follow-up experience in the Framingham study. Am J Public Health Nations Health. American Public Health Association. 1959;49:1349–56.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Canto JG, Kiefe CI, Rogers WJ, Peterson ED, Frederick PD, French WJ, et al. Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA Am Med Assoc. 2011;306:2120–7.Google Scholar
- 10.Friedlander Y. Familial clustering of coronary heart disease: a review of its significance and role as a risk factor for the disease. Genetic factors in coronary heart disease. Dordrecht: Springer; 1994. p. 37–53.Google Scholar
- 13.Andresdottir MB, Sigurdsson G, Sigvaldason H, Gudnason V, Reykjavik Cohort Study. Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors. The Reykjavik Cohort Study. Eur Heart J. 2002;23:1655–63.CrossRefPubMedGoogle Scholar
- 25.Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nat Nat Publ Group. 2007;447:661–78.Google Scholar
- 36.International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nat Nat Res. 2011;478:103–9.Google Scholar
- 38.Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nat Nat Res. 2010;466:707–13.Google Scholar
- 41.Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nat Nat Publ Group. 2010;464:409–12.Google Scholar
- 47.Goldstein BA, Knowles JW, Salfati E, Ioannidis JPA, Assimes TL. Simple, standardized incorporation of genetic risk into non-genetic risk prediction tools for complex traits: coronary heart disease as an example. Front Genet Front. 2014;5:254.Google Scholar
- 48.Salfati EL, Herrington DM, Assimes TL. Associations between a genetic risk score for clinical CAD and early stage lesions in the coronary artery and the aorta. Dubé M-P, editor. PLoS ONE. Public Libr Sci; 2016;11:e0166994.Google Scholar
- 49.Thanassoulis G, Peloso GM, Pencina MJ, Hoffmann U, Fox CS, Cupples LA, et al. A genetic risk score is associated with incident cardiovascular disease and coronary artery calcium: the Framingham Heart Study. Circ Cardiovasc Genet. American Heart Association, Inc. 2012;5:113–21.CrossRefPubMedPubMedCentralGoogle Scholar
- 51.Hindieh W, Pilote L, Cheema A, Al-Lawati H, Labos C, Dufresne L, et al. Association between family history, a genetic risk score, and severity of coronary artery disease in patients with premature acute coronary syndromes. Arterioscler Thromb Vasc Biol. American Heart Association, Inc. 2016;36:1286–92.CrossRefPubMedGoogle Scholar
- 52.Bjornsson E, Gudbjartsson DF, Helgadottir A, Gudnason T, Gudbjartsson T, Eyjolfsson K, et al. Common sequence variants associated with coronary artery disease correlate with the extent of coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. American Heart Association, Inc. 2015;35:1526–31.CrossRefPubMedPubMedCentralGoogle Scholar
- 59.Davies RW, Dandona S, Stewart AFR, Chen L, Ellis SG, Tang WHW, et al. Improved prediction of cardiovascular disease based on a panel of single nucleotide polymorphisms identified through genome-wide association studies. Circ Cardiovasc Genet. American Heart Association, Inc. 2010;3:468–74.CrossRefPubMedPubMedCentralGoogle Scholar
- 60.Bolton JL, Stewart MCW, Wilson JF, Anderson N, Price JF. Improvement in prediction of coronary heart disease risk over conventional risk factors using SNPs identified in genome-wide association studies. Xiong M, editor. PLoS ONE. Public Libr Sci; 2013;8:e57310.Google Scholar
- 62.• Abraham G, Havulinna AS, Bhalala OG, Byars SG, De Livera AM, Yetukuri L, et al. Genomic prediction of coronary heart disease. European Heart Journal. 2016;37:3267–78. This study developed a genetic risk score using the greatest number of SNPs used thus far. It demonstrated an association with cardiovascular events and an improvement in risk prediction metrics.CrossRefPubMedPubMedCentralGoogle Scholar
- 64.Buysschaert I, Carruthers KF, Dunbar DR, Peuteman G, Rietzschel E, Belmans A, et al. A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: the GRACE Genetics Study. Eur Heart J. 2010;31:1132–41.CrossRefPubMedPubMedCentralGoogle Scholar
- 67.Schunkert H, Götz A, Braund P, McGinnis R, Trégouët D-A, Mangino M, et al. Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation. American Heart Association, Inc. 2008;117:1675–84.CrossRefPubMedPubMedCentralGoogle Scholar
- 70.Patel RS, Sun YV, Hartiala J, Veledar E, Su S, Sher S, et al. Association of a genetic risk score with prevalent and incident myocardial infarction in subjects undergoing coronary angiography. Circ Cardiovasc Genet. American Heart Association, Inc. 2012;5:441–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 73.Labos C, Martinez SC, Leo Wang RH, Lenzini PA, Pilote L, Bogaty P, et al. Utility of a genetic risk score to predict recurrent cardiovascular events 1 year after an acute coronary syndrome: a pooled analysis of the RISCA, PRAXY, and TRIUMPH cohorts. Atherosclerosis. 2015;242:261–7.CrossRefPubMedPubMedCentralGoogle Scholar
- 74.• Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015;385:2264–71. This study examines the predictive capacity of a genetic risk score and also evaluates the relative benefit drawn from statin therapy based on genetic risk.CrossRefPubMedPubMedCentralGoogle Scholar
- 78.Pereira A, Mendonca MI, Sousa AC, Borges S, Freitas S, Henriques E, et al. Genetic risk score and cardiovascular mortality in a southern european population with coronary artery disease. Int J Clin. Pract 3rd ed 2017;71:e12956.Google Scholar
- 80.Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. American Heart Association, Inc; 2014. pp. 2354–94.Google Scholar
- 81.Natarajan P, Young R, Stitziel NO, Padmanabhan S, Baber U, Mehran R, et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation. American Heart Association, Inc. 2017;135:2091–101.CrossRefPubMedGoogle Scholar
- 84.• Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med. Massachusetts Medical Society; 2016;375:2349–58. This study demonstrates that standard lifestyle interventions can attenuate high cardiovascular risk mediated through genetic factors.Google Scholar
- 85.Hollands GJ, French DP, Griffin SJ, Prevost AT, Sutton S, King S, et al. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. BMJ. BMJ Publishing Group. 2016;i1102:352.Google Scholar
- 86.Kullo IJ, Jouni H, Austin EE, Brown S-A, Kruisselbrink TM, Isseh IN, et al. Incorporating a genetic risk score into coronary heart disease risk estimates: effect on low-density lipoprotein cholesterol levels (the MI-GENES clinical trial). Circulation. American Heart Association, Inc. 2016;133:1181–8.CrossRefPubMedPubMedCentralGoogle Scholar